OTCQB: GTBP

Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline

About

GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.

About

Latest News

GT Biopharma (GTBP) to Broadcast Update on TriKE Initiatives for HIV and Oncology at University of Minnesota On May 7th; Dr. Jeff Miller And Dr. Timothy Schacker to Host Event
Apr 25, 2019 • 7:30 EDT | Read More

GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
Apr 24, 2019 • 7:30 EDT | Read More

Investors

GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range